CANNADORF connects cannabis to pharma.

Cannadorf is leading the industrial large- scale growth of Cannabis tissue
culture technology for manufacturing active plant ingredients for
pharmaceutical use.

The CANNADORF Advantage


Our bioreactors allow for precise manufacturing under cGMP conditions. It is the only true and homogeneous manufacturing system for sterile pharma-grade Cannabis API and is directed toward pharmaceutical usage. With CANNADORF’s bioreactors, fast growth, consistent and reproducible
high crop yield, without loss, is enjoyed.


For intended cannabinoids and terpene content, based on known metabolic regulation genes expression from model plants, NGS and bioinformatics. This allows for the manipulation of expression of regulation genes of specific enzymes, and allows us to control the cannabinoids profile as well as increase and reduce specific metabolites for high and specific API yield.


Our innovative in-vitro micropropagation technology allows for healthy plants free from pests and diseases, significantly reduced growing space, low maintenance care, mass production, saved genetics (exact copies from the parent plant), and economic savings on space, energy, and additional expenditures.


CANNADORF’s breeding technology can reduce breeding cycles by up to five years, saving precious time and business expenses.

About Us

Our Technology

The Cannabis Tissue Culture Bioreactor

Through our unique technology, we offer pharmaceutical-grade manufacturing technology for cannabinoids to the cannabis industry. We are currently developing a cGMP bioreactor to manufacture sterile cannabis using cannabis tissue culture.

Our technology is based on many years of academic research and development with collaboration from top researchers at The Hebrew University of Jerusalem.

Benefits of Our Technology:

  • The only true and homogeneous manufacturing system for pharma-grade cannabis API, aimed toward pharmaceutical drug use

  • Trichome production by sterile tissue culture

  • Manufacturing under cGMP conditions

  • Fully sterile processes

  • Pesticide- free

  • We implement a precise process

  • Usage of a controlled environment

  • Fast growth with a consistent and reproducible high crop yield, all without yield loss

  • We facilitate biological in vivo manufacturing of essential cannabinoids and terpenes, based on known metabolic regulation gene expressions.

Genome Editing

  • For intended cannabinoids and terpene content, based on known metabolic regulation genes expression from model plants, NGS and bioinformatics
  • Expression of known early flowering genes in cannabis plants to generate small plants with multiple flowering for indoor growth and short life cycle
  • Changing the architecture of the flowers to ensure disease-free cannabis plants without yield loss
  • Metabolic engineering
  • Controlling the cannabinoids profile

In Vitro Micropropagation

  • Produces healthy plants through sterile processes with no pests and diseases, and the ability to remove viruses if needed
  • Significantly reduced growing space
  • This type of growth requires less routine attention making it quite low maintenance
  • Plants can be stored in a limited vegetative stage for longer periods
  • The number of plants can be multiplied exponentially allowing for massive production
  • With saved genetics, you gain exact copies from the mother plant
  • Benefit from reduced business expenses by saving space, energy, and more



Our bioreactors are the only true and homogeneous manufacturing system for pharma grade Cannabis API, aimed toward pharmaceutical drug use. Benefit from precise manufacturing under cGMP conditions, trichome production by sterile tissue culture, and fast growth, consistent and reproducible high crop yield– all without yield loss.

Why does it matter? With our bioreactors we are able to control gene expression and the synthesis of specific cannabinoids by genome editing in cannabis plants. Expression regulation of specific enzymes allows CANNADORF to control the cannabinoids’ profiles. This, in turn, provides the ability to increase and decrease specific metabolites for high and specific API yield.


Through CANNADORF’s micropropagation laboratory we ensure the production of healthy plants free from pests and diseases through a sterile process. With significantly reduced growing space, low maintenance care, and plants that can be stored in a limited vegetative state for longer periods of time, invaluable business expenses and logistics can be spared.


CANNADORF offers a full range of cannabinoids profile of medical cannabis, according to the Israeli IMC-GAP table. All of our strains are pathogen and disease free (virus pathogens and pests) due to sterile tissue culture reproduction process. CANNADORF will offer a library of medical cannabis strains with a consistency of cannabinoids , terpenes and flavonoids based on our unique tissue culture technology.

Our innovative tissue culture technology gives us the opportunity to supply our future customers medical cannabis plants with 100% consistency in cannabinoids, terpenes and flavonoids. Additionally, we also offer a full range of cleaning services for medical cannabis lines, and a reserve unit for plant material services.


We offer a fully automated small device solution for herbs oil extraction. Our solution is safe for users and the environment and prepares Herbs extraction from a minimum of 5 grams. It boasts an attractive price (400 USD) and is about the size of a coffee maker. It’s perfect for homemade special formulations from Cannabis and other plants.

Cannabis Pharmaceutical - Oil Bottles

Our Team

Kobi BuxdorfPh.D, M.B.A., CEO


Dr. Kobi Buxdorf is an entrepreneur and founder of CANNADORF LTD, with over 10 years of academic and industrial research and managing experience, in multidisciplinary areas in the field of microbiology, molecular biology, plant sciences, diagnostics, and medical devices. He also possesses an extended background in regulation, business development and the vision to leverage his background in science into successful commercial products.

Kobi holds a B.Sc. in Horticulture and Plant Protection (Summa Cum Laude) an M.Sc. in plant genetics and breeding (Summa Cum Laude) both from The Hebrew University of Jerusalem, an M.A. in Business Administration from the College of Management, and a Ph.D. from the Hebrew University of Jerusalem.

Eli AkselrodLL.M., Legal Advisor


Eli Akselrod has served as a partner in the Israeli law firm of Akselrod, Ohana, Amitay & co. for the last 10 years. The firm is known for its civil litigation and places an emphasis on commercial capital markets and securities law. He holds a dual degree in Business Administration and an LL.B. from Tel Aviv University (Tel Aviv, Israel), as well as an LL.M. from Northwestern University (Chicago, IL).
Dori GorenAmbassador Ret.,
Director of Business Development


Dori served in a diplomatic capacity from 1984 to 2019, mainly in South American destinations. He served as the Israeli Ambassador in Uruguay, the General Consul in Sao Paulo and South Brazil, and as the vice ambassador in Argentina. Furthermore, he was a diplomat in Paris, La Paz, El Salvador, and Brasilia. Throughout his service, he promoted relations, trade, and cooperation between Israel and Latin America.

Dori Goren has a B.A. from the Israeli National College of Security in Political Science and National Security, an M.A from the Hebrew University in Latin American Studies, History and Philosophy, and an M.A from the University of Haifa.

Advisory Board

Prof. Maggie Levy


Dr. Maggie Levy holds a Ph.D. and M. Sc. in Plant Sciences and B.Sc. in Horticulture and Plant Protection from the Robert H. Smith Faculty of Agriculture, Food and Environment, the Hebrew University of Jerusalem.

Since 2006, Maggie is a head of a laboratory in the Department of Plant Pathology and Microbiology at the Hebrew University of Jerusalem.

The research activities in Maggie’s lab are multilayered and combined of basic and applicative research that focus on plant-pathogen interactions and plant immunity. She is also an expert in plant secondary metabolites and studies their impact on fungal pathogens.

To date, Dr. Levy has granted highly competitive research grants, supervised M.Sc. and Ph.D. students and postdoctoral fellows and published an impressive number of articles in top, peer-reviewed, professional journals.

Prof. Leor Williams Eshed


Leor holds a Ph.D. (2002) from the Plant Science Department of the Weizmann Institute of Science in Rehovot, Israel, and M.Sc. (1997) from the Department of Field Crops and Genetics of the Faculty of Agriculture at The Hebrew University of Jerusalem.

Leor is the head of a laboratory studying the mechanisms of plant development, plant totipotency, and regeneration. She is an expert in tissue culture methodology, such as transformation and regeneration of reluctant plant and regeneration from protoplasts.



At CANNADORF we’re enhancing nature and leading new innovations within the cannabis industry. Please check back for career opportunities.


Fantasy networks Ltd, (FMST), a public company traded at the Tel Aviv Stock Exchange.

Private investors

Interested in investment opportunities? Let’s talk!

Do you have a question or want to request further information? Simply get in touch.

    Contact Us

    Contact us to discover opportunities!